2025 Annual report - supplemental information
Filed with HKEX · Stock code 2575 · · 3 pages · English
Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 (a joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2575) 2025 ANNUAL REPORT – SUPPLEMENTAL INFORMATION Reference is made to (i) the prospectus of Xuanzhu Biopharmaceutical Co., Ltd. (“Company”, together with its subsidiaries, the “Group”) dated October 6, 2025 (the “Prospectus”) in connected wi
Xuanzhu Biopharmaceutical Co., Ltd. on 6ix
Earlier from Xuanzhu Biopharmaceutical
- 2026 Interim report
- Voluntary announcement first patient enrolled in phase III clinical trial of anaprazole sodium for helicobacter pylori eradication
- List of directors and their role and function
Later from Xuanzhu Biopharmaceutical
- Voluntary announcement unusual price movements
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Voluntary announcement phase iii clinical study data of anaprazole sodium for reflux esophagitis presented at ueg week 2026PRESENTED at ueg week 2026
Follow Xuanzhu Biopharmaceutical into a list and get an email when it puts out news.
Follow Xuanzhu Biopharmaceutical